MA48461A - Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation - Google Patents

Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Info

Publication number
MA48461A
MA48461A MA048461A MA48461A MA48461A MA 48461 A MA48461 A MA 48461A MA 048461 A MA048461 A MA 048461A MA 48461 A MA48461 A MA 48461A MA 48461 A MA48461 A MA 48461A
Authority
MA
Morocco
Prior art keywords
excipients
viscosity
reduce
antibody formulations
formulation compositions
Prior art date
Application number
MA048461A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Jian Hua Gu
Rulin Qian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48461A publication Critical patent/MA48461A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA048461A 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation MA48461A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492049P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA48461A true MA48461A (fr) 2020-03-04

Family

ID=62148500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048461A MA48461A (fr) 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Country Status (4)

Country Link
US (2) US12257343B2 (fr)
EP (1) EP3615065A1 (fr)
MA (1) MA48461A (fr)
WO (1) WO2018200533A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109439536A (zh) * 2017-08-18 2019-03-08 黄国仁 饮用水细菌快速培养装置及菌落总数快速检测系统
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
AU2020254582B2 (en) * 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
MX2022001805A (es) * 2019-08-12 2022-06-08 Amgen Inc Formulaciones de anticuerpos anti-esclerostina.
EP4069291A1 (fr) 2019-12-03 2022-10-12 Evotec International GmbH Protéines de liaison à l'antigène associées à l'interféron et leurs utilisations
PE20230112A1 (es) * 2020-02-13 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria
PH12022552132A1 (en) * 2020-02-18 2024-01-29 Amgen Inc Formulations of human anti-tslp antibodies and methods of using the same
IL299671A (en) * 2020-07-13 2023-03-01 Merck Patent Gmbh Viscosity-reducing excipients and their combinations for high-concentration protein formulations
WO2023140807A1 (fr) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de trastuzumab
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
WO2004039337A2 (fr) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Formulations pharmaceutiques liquides stables d'anticorps ayant tendance a l'isomerisation
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
MX2009006594A (es) 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
WO2008086395A2 (fr) 2007-01-09 2008-07-17 Wyeth Préparations d'anticorps ant-il-13 et leurs utilisations
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
CN102958538A (zh) * 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
WO2012143418A1 (fr) * 2011-04-20 2012-10-26 Sandoz Ag Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
WO2013063510A1 (fr) 2011-10-28 2013-05-02 Integritybio Inc. Formulations protéiques contenant des acides aminés
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3169710A1 (fr) 2014-07-14 2017-05-24 Amgen Inc. Formulations d'anticorps cristallins
IL287947B2 (en) 2014-10-23 2024-08-01 Amgen Inc Viscosity reduction of pharmaceutical preparations
HRP20240167T1 (hr) 2017-04-28 2024-04-26 Amgen Inc. Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe

Also Published As

Publication number Publication date
EP3615065A1 (fr) 2020-03-04
US20250367115A1 (en) 2025-12-04
US12257343B2 (en) 2025-03-25
US20200352857A1 (en) 2020-11-12
WO2018200533A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA49043A (fr) Formulation stable d'anticorps
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA54052A (fr) Formulation d'anticorps
EP3621656A4 (fr) Formulation pour l'administration d'un médicament pour les yeux
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3768250A4 (fr) Formulations pour la pulvérisation d'épinéphrine
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA54139A (fr) Formulation d'anticorps
IL281938A (en) Stable semaglutide compositions and uses thereof
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3688033A4 (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
EP3625262A4 (fr) Immunoconjugués anti-folr1 et combinaisons d'anticorps anti-pd-1
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EP3817750A4 (fr) Compositions d'associations de cannabidiol
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs